Abstract
Objective
We retrospectively assessed the incidence of hemorrhagic complications associated with pacemaker implantation in patients receiving one or more antiplatelet agents.
Design and setting
Retrospective multicenter case–control study. Data were collected from three cardiac units in Germany from 2006 to 2010.
Methods
A total of 495 pacemaker patients were enrolled. 99 patients received dual antiplatelet therapy (aspirin and clopidogrel), 198 were given only aspirin and 198 had no antiplatelet therapy (control). Patients were matched for age and sex. Implant-related bleeding complications were defined as major bleeding, if surgical pocket exploration or blood transfusion were needed. Minor bleeding complications were defined as one or more of the following conditions: fall of hemoglobin content >1.5 g/dl not requiring blood transfusion; pocket hematoma; pocket effusion not requiring surgical revision.
Measurements and results
Hemorrhagic complications were seen in 4/198 control patients and 6/198 aspirin-only patients [2 vs. 3 %, p = 0.5, OR = 1.52 (0.42–5.46)]. Patients undergoing dual antiplatelet therapy had significantly more bleeding complications than patients in the aspirin-only group [11/99: 11.1 vs. 3 %, p = 0.005, OR = 3.95 (1.43–11.16)]. Major complications occurred in 1/198 control patients and 2/198 aspirin-only patients [0.5 vs. 1 %, p = 0.6, OR = 2.01 (0.18–22.35)]. In contrast, 7/99 patients undergoing dual antiplatelet therapy exhibited major complications [7.1 vs. 1 %, p = 0.004, OR = 7.46 (1.52–36.50)].
Conclusions
Although in patients undergoing pacemaker implantation dual antiplatelet therapy with aspirin and clopidogrel caused a significant increase of bleeding complications, the use of aspirin alone was not associated with a significant increase in bleeding complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antithrombotic Trialists′ Collaboration (2002) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86
Popma JJ, Berger P, Ohman EM et al (2004) Antithrombotic therapy during percutaneous coronary intervention. Chest 126:567–599
Said SM, Hahn J, Schleyer E et al (2007) Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia. Clin Res Cardiol 96:61–69
Tompkins C, Cheng A, Dalal D et al (2010) Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter–defibrillator device implantation. J Am Coll Cardiol 55:2376–2382
Kutinsky IB, Jarandilla R, Jewett M, Haines DE (2010) Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 3:312–318
Ellenbogen KA, Hellkamp AS, Wilkoff BL et al (2003) Complications arising after implantation of DDD pacemakers: The MOST experience. Am J Cardiol 92:740–741
Wiegand UK, LeJeune D, Boguschewski F et al (2004) Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 126:1177–1186
Conflict of interest
No company or third party has sponsored this study, and for none of the authors there exists a conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
S. M. Said and H. D. Esperer contributed equally to this manuscript.
Rights and permissions
About this article
Cite this article
Said, S.M., Esperer, H.D., Hahn, J. et al. Influence of oral antiplatelet therapy on hemorrhagic complications of pacemaker implantation. Clin Res Cardiol 102, 345–349 (2013). https://doi.org/10.1007/s00392-013-0543-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-013-0543-8